In the present study, which involves the largest patient population reported on to date, we attempted to clarify the role of SRS and to identify associated factors of prog nostic significance.
Methods
The University of Pittsburgh Institutional Review Board approved this retrospective study.
Patient Population
From our database of over 9700 radiosurgical pa tients, we identified 350 women (median age 54 years, range 29-84 years) who had undergone SRS for 1535 brain metastases between May 1990 and March 2009. The median number of brain metastases per patient was 2 (range 1-18 metastases). Medical or radiation oncologists had referred each patient for radiosurgery consideration. Resection was advocated for larger tumors (> 3 cm in di ameter) with mass effect unresponsive to corticosteroid therapy. Patients with 1-4 metastases underwent radio surgery alone, and those with 5 or more tumors typically received WBRT plus radiosurgery (before 2000) or ra diosurgery alone as initial therapy (since 2000). All pa tients underwent repeat highresolution MR imaging 8 weeks later. If new tumors were identified, WBRT was then considered if it had not been previously delivered. Medical and radiation oncologists commonly requested radiosurgery alone as initial therapy since it allowed for the continuation of any extracranial cancer care. Patient characteristics are shown in Table 1 . The median interval between primary site diagnosis and the diagnosis of brain metastases was 46 months (range 0-305 months).
Ten patients (3%) had brain metastases in the context of no active systemic disease. Fortysix patients (13%) with extracranial metastases had control of that disease at the time of brain tumor management.
At the time of SRS, 125 patients (36%) were asymp tomatic, 42 (12%) had headache only, 13 (4%) had a sei zure only, 161 (46%) had focal neurological deficits, and 9 (3%) had cognitive disorders. The median KPS score was 100% (range 40%-100%). When stratified according to the prognostic value of the RPA devised by the RTOG, 18, 19 24 (6.9%) were in Class 1, 310 (88.6%) were in Class 2, and 16 (4.6%) were in Class 3.
The HER2/neu status was analyzed via immunohis tochemical testing on the primary site specimens with ap propriate positive and negative controls using monoclonal antibody 4B5 (Ventana). The HER2 3+ staining (> 30% of cells exhibiting strong perimembranous staining) was considered positive, whereas HER2 2+ staining (weak staining in > 10% of cells) was considered equivocal. The HER2 testing was performed using fluorescence in situ hybridization with a fluorescent DNA probe for HER2 (Vysis, Inc.) and fluorescence microscopy. At least 50 nuclei were counted per specimen. A ratio > 2.2 of the HER2 gene probe/chromosome 17 centromere probe was considered positive. A ratio of 1.8-2.2 was considered equivocally positive, whereas a ratio < 1.8 was consid ered negative.
Radiosurgery Technique
Our radiosurgical technique has been described in detail in previous reports.
14 In brief, patients underwent the application of an imagingcompatible stereotactic head frame while under local anesthesia supplemented with intravenous conscious sedation. Highresolution MR imaging or rarely CT was then performed. The tumor was visualized using 2mm contrastenhanced volume acquisition images supplemented by 3mm T2weighted sequences. The SRS target was defined as the contrastenhanced tumor volume.
The median volume for each individual tumor was 0.7 cm 3 (range 0.01-48.9 cm 3 ). The median volume of the largest tumor per patient was 3.2 cm 3 (range 0.06-48.9 ). A median of 5 isocenters (range 1-34 isocenters) was used for dose planning in each patient. The median prescription dose delivered to the tumor margin was 17.0 Gy (range 8-23 Gy). The max imum dose varied from 18 to 42.5 Gy (median 32.0 Gy). Stereotactic radiosurgery was performed using a Model U, B, C, 4C, or Perfexion Leksell Gamma Knife (Elekta, Inc.). The addition of the Perfexion Leksell Gamma Knife facilitated singlesession treatment in patients with mul tiple metastases, especially those who had experienced a relapse after prior WBRT. The largest number of metas tases treated in a single procedure in this experience was 18.
All patients received a 20 to 40mg intravenous dose of methylprednisolone after radiosurgery to reduce the risk of early brain swelling. For patients already tak ing corticosteroids, the medication was tapered over 1-3 weeks. Patients were evaluated and imaging studies were obtained at regular intervals. Typically, we performed MR imaging 2 months after radiosurgery, at 3month intervals thereafter for the first 2 years, every 6 months until Year 5, and then annually thereafter. Radiological outcome was classified as "tumor progression" if the tumor volume increased by > 25% compared with its size at the time of SRS and as "tumor regression" if a > 25% volume reduc tion was noted. A tumor was deemed "stable" on followup MR imaging if it remained within 25% of its initial volume. We diagnosed continuously enlarging enhanc ing lesions as tumor recurrences and stable or decreasing enhancing lesions as radiation effects after a temporary course of corticosteroids if symptomatic. Adverse radia tion effects were evaluated according to the late radiation morbidity criteria of the RTOG and the EORTC. 10 
Statistical Analysis
We constructed KaplanMeier plots for survival and the local tumor control rate by using the dates of primary cancer diagnosis, brain metastasis diagnosis, and SRS. The local tumor control rate and OS time were calculated from the day of the first SRS by using the Kaplan-Meier method. Univariate analysis was performed on the Ka planMeier curves by using the logrank statistic and the Cox proportional hazards model, with p < 0.05 set as the level of significance. We performed multivariate analysis using the Cox proportional hazards model, with p < 0.05 set as significant. Standard statistical processing software (SPSS, version 15.0, SPSS, Inc.) was utilized. Univariate and multivariate analyses were performed to assess the prognostic value of different variables relative to tumor response, distant failure, and patient survival. Variables for multivariate analysis were those with statistical sig nificance on univariate analysis.
Results

Patient Survival
At the time of our assessment, 72 patients (21%) were alive and 278 patients (79%) had died. The median fol lowup was 9.5 months (range 0. Table 2 ). The median survival of those with (227 patients) and without (123 patients) prior WBRT was 10.3 (95% CI 7.87-12.73) and 14.2 months (95% CI 9.53-18.81 months), respectively.
Tumors from 119 (50%) of 240 patients who were evaluated for estrogen receptor status were positive. One hundred fourteen (59%) of 192 patients who were evalu ated for HER2/neu status demonstrated overexpression. Estrogen receptor status was not associated with patient survival (p = 0.428). Patients with HER2/neu overexpres sion had 6, 12, 24 and 36month OSs of 79%, 59%, 42%, and 31%, respectively. The MST of patients with HER2/neu overexpression was 14.5 months after SRS (95% CI 11.43-17.63 months). Patients without HER2/ neu overexpression had a 6, 12, 24, and 36month OSs of 57%, 45%, 18%, and 7%, respectively, and a median survival of 8.3 months (95% CI 3.03-13.57 months) after SRS. Thus, patients with HER2/neu overexpression lived longer (p < 0.0005; Fig. 3 ).
On multivariate analysis, factors associated with lon ger survival times included controlled extracranial dis ease (p = 0.002, HR = 1.887), KPS score ≥ 70 (p = 0.003, HR = 2.628), smaller total tumor volume (p = 0.002, HR = 1.028), absence of brainstem metastases (p = 0.042, HR = 1.880), and overexpression of HER2/neu (p < 0.0005, HR = 1.932; Table 3 ).
New Remote Brain Tumors
Followup imaging was available for 266 patients, and new brain metastases were found on imaging studies in 125 patients (47%). The survival rate without a new tu mor after SRS was 72%, 48%, 34%, and 22% at 6, 12, 24, and 36 months, respectively. The median time free from another tumor was 11.6 months (95% CI 10.12-13.02 months). Fifty-five (59%) of 94 patients who did not re ceive WBRT had new remote brain metastases, whereas 71 (41%) of 172 patients who did receive WBRT had new remote brain metastases. According to the Fisher exact test, prior WBRT was associated with a lower rate of new brain disease (p = 0.012); however, the median time to the discovery of a new remote tumor was 11.6 or 11.5 months for patients who had no prior or prior WBRT (p = 0.4), respectively.
On univariate analysis, factors associated with a lon ger time without new brain disease included controlled extracranial disease (p = 0.005), lower number of me tastases at the time of SRS (as a continuous variable, p = 0.010; dichotomized to ≤ 3 metastases, p = 0.076; or dichotomized to < 5 metastases, p = 0.011), and absence of lung metastases (p = 0.030; Table 2 ). The median time free from new brain disease if the presentation was a soli tary tumor, 2-4 tumors, and 5 or more tumors before GKS was 15.3, 11.4, and 8.8 months, respectively (Fig. 4) .
On multivariate testing, factors associated with a lon ger time without new brain disease included controlled Table 3 ). Estrogen receptor status and HER2/neu status were not associated with the development of new remote brain metastases
Local Tumor Control
Two hundred sixtysix patients with followup imag ing studies had 1115 tumors (managed in a total of 525 radiosurgical procedures). Followup imaging occurred at a median of 7.3 months (range 0.4-144 months). The best response obtained was complete disappearance of 217 tumors (19%). Regression was noted in 513 tumors (46%), no change was found in 272 lesions (24%), and progression was documented in 113 (10%). Progression free survival after SRS was 90%, 71%, 58%, and 50% at 6, 12, 24, and 36 months, respectively.
On univariate analysis, factors associated with lon ger PFS included a lower RPA class (p = 0.030), fewer metastases at the time of SRS (as a continuous variable, p = 0.001; dichotomized to solitary metastasis, p = 0.025; or dichotomized to ≤ 3 metastases, p < 0.0001), no prior WBRT (p = 0.003), smaller total tumor volume (as a con tinuous variable, p < 0.0001; or dichotomized to < 8 cm 3 , p < 0.0005), smaller volume for the largest tumor in each patient (continuous variable, p < 0.0001), presence of cer ebellar metastases (p < 0.0001), margin dose ≥ 17 Gy (p < 0.0005), and each tumor volume < 3 cm 3 (p < 0.0001; Table 2 ).
On multivariate analysis, factors associated with a longer PFS included a KPS score ≥ 70 (p = 0.019, HR = 3.432), no prior WBRT (p = 0.015, HR = 2.053), and smaller total tumor volume (p < 0.0001, HR = 1.053; Ta ble 3).
Clinical Outcomes
Clinical followup information was available in 275 patients. Note that this information was unavailable in 75 patients because of the shorter interval between SRS and death. There were no deaths after SRS. Sixteen pa tients (6%) had symptomatic AREs. Symptoms resolved completely after a temporary course of corticosteroids in 13 patients. Ten of 13 patients had hemiparesis with headache (RTOG/EORTC Grade 3). The remaining 3 patients (1.1%), who had a declined level of conscious ness, required a resection (RTOG/EORTC Grade 4); 2 of these patients had confirmed radiation necrosis, and 1 had mixed necrosis and persistent tumor. Asymptomatic AREs were noted in another 14 patients (5%). In total, suspected or confirmed AREs were detected in 11% of patients. Adverse radiation effects were noted at a me dian of 6 months (range 1.6-74.5 months) after treatment. On univariate analysis, a larger total tumor volume (con tinuous variable, p = 0.012) and a largervolume tumor (continuous variable, p < 0.0005) were significantly as sociated with a higher incidence of AREs. Prior WBRT, patient age, tumor margin dose, number of tumors, and tumor location were not associated with the incidence of AREs.
Preexisting neurological symptoms improved in 54 patients (20%), including headache (8 patients [3%]), fo cal neurological deficits (43 patients [16%]), and cognitive dysfunction (3 patients [1%]). Neurological symptoms re mained unchanged in 83 patients (30%). All 87 patients who had no neurological symptoms at the time of SRS 
Further Management After Radiosurgery
After SRS, 11 patients (4%) required craniotomy and resection due to local tumor progression (8 patients) or AREs (3 patients). One hundred eight patients (39%) re quired additional repeat SRS, which was performed for the management of delayed tumor progression ( 
Discussion
The development of 1 or more brain metastases in a patient with breast cancer is an ominous event. Treat ment options include resection, WBRT, and SRS, either alone or in combination. Historically, breast carcinoma has been considered a relatively radiosensitive tumor. 27 Accordingly, WBRT has been advocated for many pa tients. 7, 25 More recently, however, the role of WBRT has been called into question because of the risk of delayed neurocognitive dysfunction in longerterm survivors. In the short term, most patients suffer fatigue and hair loss. Systemic treatment with chemotherapy is typically sus pended during WBRT. 32 Resection remains of value for tumors with symptomatic mass effect but must be fol lowed by adjuvant WBRT or tumor bed radiosurgery to improve local tumor control. Magnetic resonance imag ing as a brain staging tool often detects brain metastases that are small or asymptomatic. Stereotactic radiosurgery has been used with increasing frequency in patients with brain metastases regardless of the histological type. Sev eral retrospective studies have compared outcomes in pa tients treated using SRS with or without WBRT. 17, 29, 32, 33 Those studies have generally shown that recurrence rates are reduced by adjuvant WBRT, although total survival is not increased. 28 Aoyama et al. 4 compared the results of SRS alone versus SRS plus WBRT. They noted no improvement in survival for patients with 1-4 brain me tastases, although intracranial progression occurred more frequently in those who had not received WBRT. Chang et al. 8 compared the neurocognitive results of SRS alone versus SRS plus WBRT in a randomized controlled trial of 1-3 newly diagnosed brain metastases. They found that patients who underwent SRS plus WBRT were at a great er risk of a significant decline in learning and memory function by 4 months as compared with the group that had received SRS alone. The authors recommended that radiosurgery alone combined with close clinical monitor ing should be the preferred approach in such patients. Sur gical salvage should be used for local failures, and SRS or WBRT should be used for distant failures as indicated.
Patients with brain metastases from breast cancer may live longer than patients with other metastatic can cers because of improving responses to extracranial dis ease management. The longer survival of these patients has necessitated the study of this cohort separately from other cohorts with heterogeneous brain metastases. 9 To date, the overall prognosis of patients with brain metas tases from breast carcinoma remains unclear, due in part to vaguely defined selection criteria, insufficient followup data, and variations in the treatment regimens. 14, 15, 23, 25 The unique molecular features of breast cancer allow for tailored therapeutic approaches that might improve the response of both extra and intracranial disease manifes tations (using agents such as trastuzumab, lapatinib, and aromatase inhibitors).
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Patient Survival
Median survival times varying from 8 to 19 months have been reported by other centers after SRS with or without WBRT in patients with brain metastases from breast carcinoma (Table 4) .
1,2,9,14,20,23,27 Muacevic et al. 27 documented 151 patients with 620 brain metastases. The MST after SRS was 10 months. A KPS score > 70 and an RPA Class 1 were related to prolonged survival. Patients with RPA Class 1, 2, and 3 survived 35, 9, and 8 months, respectively. The reason for such a large difference be tween RPA Class 1 and Class 2 patients is unclear. In our series, the median survivals were 17 months for RPA Class 1 and 11 months for Class 2 patients. In a recent se ries, Kased et al. 22 described their results for 176 patients with breast cancer metastases. The MST was 16.0 months for 95 patients with newly diagnosed disease and 11.7 months for 81 patients with recurrent brain metastases. Longer survival was associated with an age < 50 years, a KPS score ≥ 70, primary tumor control, estrogen receptor positivity, and HER2/neu overexpression. In our series, HER2/neu overexpression was also significantly associ ated with longer survival (p < 0.0005, HR = 2.025). Da wood et al. 11 reported that HER2/neu overexpression was associated with longer patient survival and a longer time to brain metastases than HER2/neu-negative disease.
DiLuna et al. 12 described their results in 334 patients with intracranial brain metastases from a variety of pri mary cancer origins. In that series, 16% of patients had breast cancer. In the entire series, survival was signifi cantly better in patients who had 1-3 metastases (MST = 8.5 months) as compared with those who had > 4 metas tases (MST = 6.3 months; p = 0.03). In our study, patient survival was significantly longer in those who had < 5 brain metastases (MST = 12.2 months) compared with patients who had > 5 metastases (MST = 10.8 months; p = 0.049).
In our series, a larger total tumor volume per patient and an increased volume of the largest tumor were signif icantly associated with worse patient survival. Akyurek et al. 1 also found that a smaller total target volume sig nificantly prolonged survival in patients with recurrent breast cancer metastases, but not in patients with newly diagnosed disease. The possibility that smaller tumors were treated with higher doses may be a confounding variable. Perhaps, not surprisingly, prior WBRT was sig nificantly associated with shorter patient survival given the likelihood that patients who received WBRT had both a greater number of brain metastases (p < 0.0001) and a larger total tumor volume (p < 0.0001). Whenever possi ble, we treated patients with more favorable prognoses by using SRS alone and reserving WBRT for patients with multiple metastases (typically > 4). There is current inter est in using SRS alone in all patients regardless of the number of tumors. Patients undergo repeat MR imaging at 2 months. If new tumors are found, WBRT or salvage SRS can be offered. Since many patients are living lon ger and are at risk for late leptomeningeal carcinomatosis (for which WBRT is the preferred treatment), we prefer to save WBRT for a time when it is truly required. A ran domized prospective study may help to define the role of WBRT in patients with brain metastases from breast can cer, emphasizing survival, tumor control, complications, and the risk of neurocognitive dysfunction.
Distant Tumor Control
New brain metastases developed after SRS in 47% of the patients in our series. We found that prior WBRT was associated with a lower risk of new brain metastasis, al though new disease requiring management still developed in 42% of patients. Factors associated with the develop ment of distant new brain tumors were active extracranial disease and a higher number of brain metastases at the time of SRS, perhaps related to more active systemic dis ease from the onset. Akyurek et al. 1 reported that active primary disease, a younger age, and negative estrogen re ceptor status was associated with the development of dis tant new brain metastases. In our series, estrogen receptor status and HER2/neu overexpression were not associated with distant new brain metastases; however, we did find that the presence of lung metastases was significantly as sociated with distant new brain metastases (p = 0.001, HR = 1.93). Patients with lung metastases from breast cancer had 2 times the risk of distant new brain tumors as com pared with patients without them. Prior WBRT was as sociated with a lower rate of new brain disease, although it did not affect the interval between GKS and new brain disease.
Local Tumor Control
Sustained local tumor control was achieved in 90% of tumors and 75% of patients. Progressionfree survival after SRS was 90% at 6 months and 71% at 1 year. Ac cording to previous reports, 1year PFS varies from 73% to 90%. 22 We found that factors associated with a longer PFS included a better RPA class and fewer metastases at the time of SRS. Progressionfree survival is better in patients who have not undergone prior WBRT. Patients without prior WBRT have a significantly larger number of brain metastases (p < 0.0001, MannWhitney Utest) and a larger total tumor volume (p < 0.0001, MannWhitney Utest) than patients with prior WBRT. These outcomes might have made prior WBRT a predictor of longer PFS.
Adverse Radiation Effects
Adverse radiation effects were detected on followup imaging in 11% of patients, onehalf (6%) with neurologi cal symptoms. A larger total tumor volume (p = 0.012) and the volume of the largest tumor (p < 0.0005) were significantly associated with a higher incidence of AREs. Kased et al. 22 also reported that symptomatic radiation effects occurred in 6% of patients, and half of these cases required resection. Muacevic et al. 27 described symptom atic radiation effects after SRS in 11% of patients and asymptomatic AREs in 9%. In the present study, neuro logical symptoms remained stable or improved in 82% of the patients, and 64% of patients were gradually weaned from corticosteroids after SRS if they had been using them beforehand.
Conclusions
Stereotactic radiosurgery is an effective management option for primary and recurrent brain metastases from breast cancer. Radiosurgery provides early and safe brain tumor management for the majority of presenting patients and allows extracranial management to continue uninter rupted. Note, however, that total survival is related to the control of extracranial disease. The current role and tim ing of WBRT for breast cancer brain metastases remains unclear. A prospective study is needed to better define the benefit and risks of WBRT in patients with brain metas tases from breast cancer.
